BPC-157 (10 mg vial) dosage protocol

1. Draw 3 mL of bacteriostatic water with a sterile syringe.
2. Inject it slowly down the inside wall of the vial, not onto the powder, to avoid foaming.
3. Swirl or roll the vial gently until the powder dissolves. Do not shake it.
4. Label it with the date and the volume of water, and refrigerate at 2-8 °C (36-46 °F), away from light.

• Reconstitute: add 3 mL of bacteriostatic water for a 3.33 mg/mL solution.
• Amounts in the chart: 200 mcg-600 mcg each time, by subcutaneous injection, once a day.
• Easy measuring: at 3.33 mg/mL, one unit (0.01 mL) on a U-100 insulin syringe holds about 33.3 mcg.
• Storage: freeze-dried, keep it sealed, cold and away from light (frozen for long storage). Once mixed, refrigerate at 2-8 °C and avoid freezing and thawing.

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. Almost all of its research is in animals, and it is not FDA-approved.

• Primary calculation: 10 mg made up to 3 mL equals 3.33 mg/mL.
• Amounts shown: 200 mcg-600 mcg per administration. Reported in the research community. It has not been tested as a schedule in human trials.
• Route and frequency: subcutaneous injection, once a day.
• Evidence ceiling: 3 of the 14 studies with a dose in our library were done in people.
• Regulatory status: Not FDA-approved for any use. In April 2026 the FDA removed it from Category 2 of the 503A bulks list; that is not an approval, and its compounding status is still under review. WADA: Prohibited at all times (S0, non-approved substances).

A 10 mg vial holds 10,000 mcg of BPC-157. Adding 3 mL gives 3.33 mg/mL, so one U-100 unit (0.01 mL) holds 33.3 mcg. To get the units for an amount, divide it by 33.3 mcg. The units are a volume mark on the syringe, not a measure of potency.

• 200 mcg: 0.06 mL, or 6 U-100 units.
• 400 mcg: 0.12 mL, or 12 U-100 units.
• 600 mcg: 0.18 mL, or 18 U-100 units.

Vial coverage by mass: 50 full amounts of 200 mcg, 25 full amounts of 400 mcg, 16 full amounts of 600 mcg per vial, before any handling loss.

If a different volume of water is used, every unit figure changes: recalculate with the calculator above.

Three small human reports exist, all from the same US clinic and journal, and none with a control group or blinding:

• Knee pain: a chart review of 16 patients given injections into the knee. Most said their pain improved when asked months later, but this was self-reported, with no comparison group or imaging (Lee 2021).
• Interstitial cystitis: 12 women who had not responded to standard treatment received a single 10 mg treatment injected into the bladder wall. Ten reported their symptoms resolved (Lee 2024).
• Intravenous safety: two healthy adults received infusions of up to 20 mg with no reported adverse effects (Lee 2025).

A 2026 systematic review found only these three studies (30 people in total), judged all of them poor quality, and rated the certainty of the evidence as very low (Poolton 2026). In short: there is no reliable evidence yet that BPC-157 works or is safe in people.

Doses used in human studies

• Lee E 2025: Infusions of up to 20 mg (Intravenous infusion)
• Lee E 2024: 10 mg in total, in a single procedure (Injected into the bladder wall during cystoscopy)

Every study dose, including animal and cell studies, is in the BPC-157 dose table.

Side effects and long-term safety in people are unknown: the human reports include about 30 people, without control groups. Animal toxicology from the group developing it in China found no serious toxicity in mice, rats, rabbits and dogs (Xu 2020), but animal safety does not establish human safety.

• Product quality: BPC-157 sold online is not checked by any regulator for identity, purity, dose or sterility. Reviews in orthopaedics highlight unregulated manufacturing as a main risk (Vasireddi 2025; McGuire 2025).
• Blood vessel growth: its main proposed effect is promoting new blood vessels. Tumours also depend on new vessels, so this is a theoretical concern for anyone with cancer or a history of it. It has not been studied.
• Injection risks: any injected product that is not sterile can cause infection or abscesses.
• Sport: it is on the WADA prohibited list at all times, so athletes subject to testing can be sanctioned.

• FDA: Not FDA-approved for any use. In April 2026 the FDA removed it from Category 2 of the 503A bulks list; that is not an approval, and its compounding status is still under review.
• WADA: Prohibited at all times (S0, non-approved substances).
• Evidence limits: reported use is not evidence that a schedule works or is safe. Animal doses do not convert to people, and research products are not made or checked for use in people.
• Status checked on: Oct 26, 2026.